Steinman Lawrence, Zamvil Scott S
Department of Neurology and Neurological Sciences, Stanford University, CA 94305, USA.
Ann Neurol. 2006 Jul;60(1):12-21. doi: 10.1002/ana.20913.
In their Point of View entitled "Experimental Allergic Encephalomyelitis: A Misleading Model of Multiple Sclerosis," Sriram and Steiner(1) wrote, "The most disappointing aspect of EAE [experimental allergic encephalomyelitis] as a potential model for MS is its almost total inability to point toward a meaningful therapy or therapeutic approach for MS." Actually, EAE has led directly to the development of three therapies approved for use in multiple sclerosis (MS): glatiramer acetate, mitoxantrone, and natalizumab. Several new approaches to MS are in clinical trials based on positive indications in preclinical work relying on EAE. New clues to the pathogenesis of MS and new potential surrogate markers for MS are shown from research involving EAE when it is critically coupled with actual findings in MS. There are pitfalls in overreliance on the EAE model, or on any animal model for any human disease. Nevertheless, over the past 73 years, the EAE model has proved itself remarkably useful for aiding research on MS.
在他们题为《实验性自身免疫性脑脊髓炎：多发性硬化症的误导性模型》的观点文章中，斯里拉姆和施泰纳写道：“作为多发性硬化症潜在模型，实验性自身免疫性脑脊髓炎（EAE）最令人失望的方面在于，它几乎完全无法指向针对多发性硬化症的有意义的治疗方法。”实际上，EAE直接促成了三种被批准用于治疗多发性硬化症（MS）的疗法的研发：醋酸格拉替雷、米托蒽醌和那他珠单抗。基于在依赖EAE的临床前研究中的阳性指征，几种针对MS的新方法正在进行临床试验。当EAE与MS的实际发现紧密结合时，涉及EAE的研究揭示了MS发病机制的新线索以及MS新的潜在替代标志物。过度依赖EAE模型或任何人类疾病的动物模型都存在缺陷。然而，在过去73年里，EAE模型已证明自身在辅助MS研究方面非常有用。
